PredictImmune
Prognostic tools for guiding personalised treatment options in immune-mediated diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
$48—73m (Dealroom.co estimates Jul 2019.)
Company register number 10563794
Babraham England (HQ)
Financials
Estimates*
EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Revenues | - | - | <1m | <1m | <1m | <1m |
% growth | - | - | - | 25 % | 22 % | (2 %) |
EBITDA | (2.4m) | (4.4m) | (5.3m) | (2.6m) | (2.6m) | - |
% EBITDA margin | - | - | (8602 %) | (3313 %) | (2762 %) | - |
Profit | (2.4m) | (4.1m) | (4.7m) | (3.3m) | (2.0m) | - |
% profit margin | - | - | (7530 %) | (4207 %) | (2127 %) | - |
R&D budget | - | - | 1.2m | <1m | - | - |
R&D % of revenue | - | - | 1901 % | 1271 % | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Spinout | ||
£4.7m | Series A | ||
* | £4.3m | Grant | |
£100k | Grant | ||
€11.0m | Series B | ||
* | N/A | N/A | Grant |
Total Funding | $24.1m |
Recent News about PredictImmune
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.